David Lebowitz
Stock Analyst at Citigroup
(4.33)
# 397
Out of 5,102 analysts
119
Total ratings
59.77%
Success rate
14.73%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $79.14 | +6.14% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $60.77 | +38.23% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $27.94 | +71.80% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $18.13 | +10.31% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $210.16 | +37.99% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $96.10 | +7.18% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $37.21 | +2.12% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $40.04 | -45.05% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $74.07 | -9.54% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $41.39 | +35.30% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $9.55 | +4.71% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.32 | +13.64% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $75.44 | -40.35% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $65.72 | +3.47% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $571.33 | -33.14% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $52.99 | +81.17% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $6.20 | +93.55% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $412.63 | -60.25% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $29.47 | +32.34% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $20.41 | +2.89% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $7.00 | +5,685.71% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.68 | +280.43% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $79.14
Upside: +6.14%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $60.77
Upside: +38.23%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $27.94
Upside: +71.80%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $18.13
Upside: +10.31%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $210.16
Upside: +37.99%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $96.10
Upside: +7.18%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $37.21
Upside: +2.12%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $40.04
Upside: -45.05%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $74.07
Upside: -9.54%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $41.39
Upside: +35.30%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $9.55
Upside: +4.71%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.32
Upside: +13.64%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $75.44
Upside: -40.35%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $65.72
Upside: +3.47%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $571.33
Upside: -33.14%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $52.99
Upside: +81.17%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $6.20
Upside: +93.55%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $412.63
Upside: -60.25%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $29.47
Upside: +32.34%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $20.41
Upside: +2.89%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $7.00
Upside: +5,685.71%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.68
Upside: +280.43%